IFN-γ Reporter HEK 293 Cells
HEK-Blue™ IFN-γ cells | Unit size | Cat. code | Docs | Qty | Price |
---|---|---|---|---|---|
Human HEK293 cells - IFN-γ Reporter Cells |
3-7 x 10e6 cells |
hkb-ifng |
You may also need : QUANTI-Blue™ | View more associated products ▼
Human Interferon-γ Reporter Cells
HEK-Blue™ IFN-γ Cells signaling pathway
HEK-Blue™ IFN-γ cells allow the detection of bioactive human interferon-γ (IFN-γ) by monitoring the activation of the JAK/STAT-1 pathway.
IFN-γ, a Type II IFN, is a pleiotropic cytokine with anti-viral, anti-tumor, and immunomodulatory functions [1]. IFN-γ binds a heterodimeric receptor consisting of two subunits, IFNGR1 and IFNGR2, associated with JAK1 and JAK2, respectively. Upon binding to this receptor, IFN-γ triggers JAK/STAT signaling. Activated STAT1 molecules form homodimers and are translocated to the nucleus where they bind interferon-gamma-activated sites (GAS) in the promoter of IFN-γ inducible genes.
Cell line description:
HEK-Blue™ IFN-γ cells were generated by stable transfection of the human embryonic kidney HEK293 cell line with the human STAT1 gene to obtain a fully active STAT1 pathway.
The other genes of the pathway are naturally expressed in sufficient amounts.
These cells were further transfected with a SEAP (secreted embryonic alkaline phosphatase) reporter gene under the control of an ISG54 promoter fused to four interferon-gamma-activated sites (GAS).
HEK-Blue™ IFN-γ cells produce SEAP in response to IFN-γ stimulation only. They are unresponsive to type I IFNs.
Levels of SEAP in the supernatant can be easily determined with QUANTI-Blue™ Solution.
Features of HEK-Blue™ IFN-γ cells:
- Fully functional IFN-γ signaling pathway
- Do not respond to IFN-α/β (Type I IFNs)
- Readily assessable SEAP reporter activity
- Functionally tested and guaranteed mycoplasma-free
Applications of HEK-Blue™ IFN-γ cells:
- Detection of human IFN-γ
- Screening of anti-hIFN-γ antibodies
Reference:
1. Ivashkiv L.B., 2018. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 18(9):545-558.
Back to the topSpecifications
Antibiotic resistance: blasticidin, Zeocin®
Growth medium: DMEM, 4.5 g/l glucose, 2 mM L-glutamine, 10% (v/v) heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, 100 μg/ml Normocin™
Guaranteed mycoplasma-free
Detection range for human IFN-γ: 0.1 - 10 ng/ml
This product is covered by a Limited Use License (See Terms and Conditions).
Back to the topContents
- 1 vial containing 3-7 x 106 cells
- 1 ml of Blasticidin (10 mg/ml)
- 1 ml of Zeocin® (100 mg/ml)
- 1 ml of Normocin™ (50 mg/ml)
- 1 ml of QB reagent and 1 ml of QB buffer (sufficient to prepare 100 ml of QUANTI-Blue™ Solution, a SEAP detection reagent)
Shipped on dry ice (Europe, USA, Canada and some areas in Asia)
Details
Interferon-gamma (IFN-γ), a Type II interferon, is secreted from CD4+ T-helper 1 (Th1) cells and activated natural killer (NK) cells. It plays a role in activating lymphocytes to enhance anti-microbial and anti-tumor effects [1-3]. In addition, IFN-γ plays a role in regulating the proliferation, differentiation, and response of lymphocyte subsets.
IFN-γ exerts its action by first binding to a heterodimeric receptor consisting of two chains, IFNGR1 and IFNGR2, causing its dimerization and the activation of specific Janus family kinases (JAK1 and JAK2) [4, 5]. Two STAT1 molecules then associate with this ligand-activated receptor complex and are activated by phosphorylation. Activated STAT1 forms homodimers and are translocated to the nucleus where they bind interferon-gamma-activated sites (GAS) in the promoter of IFN-γ inducible genes.
1. Ivashkiv L.B., 2018. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol. 18(9):545-558.
2. Shtrichman R. & Samuel CE., 2001. The role of gamma interferon in antimicrobial immunity. Curr Opin Microbiol. 4(3):251-9.
3. Sato A. et al., 2006. Antitumor activity of IFN-lambda in murine tumor models. J Immunol. 176(12):7686-94.
4. Platanias L.C., 2005. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 5(5):375-86.
5. Schroder K. et al., 2004. Interferon-gamma: an overview of signals, mechanisms, and functions. J Leukoc Biol. 75(2):163-89.